Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
Positive associations between galectin-3 and PSA levels in prostate cancer patients: a prospective clinical study-I.
复制标题
DOI：
10.18632/oncotarget.12619
复制
发表时间：
2016-12-13
期刊：
影响因子：
--
通讯作者：
Raz A
中科院分区：
文献类型：
--
作者：
Nakajima K;Heilbrun LK;Hogan V;Smith D;Heath E;Raz A
半乳糖凝集素-3（Gal-3）是一种致癌的促炎蛋白，已被建议作为前列腺癌患者前列腺特异性抗原（PSA）血液检测的可能补充诊断候选物。循环中蛋白质（生物标志物）的存在可能通过产生自身抗体引发内在体液免疫反应，从而可能改变检测水平。在这里，我们报告了两种前列腺癌生物标志物Gal-3和PSA在不同临床状态的前列腺癌患者中的相关性，同时考虑到自身抗体水平。进行了一项盲法、前瞻性、单机构、初步研究。共95名男性被分为5组：健康对照组（第1组），新诊断的患者（第2组），局部治疗后无复发（第3组），局部治疗后PSA升高（第4组）和转移性患者（第5组）。Gal-3和PSA水平除以其各自的自身抗体，得到相对PSA和相对Gal-3水平。经过调整后，斯皮尔曼的等级相关和线性回归模型显示，在所有95名男性中，相对Gal-3和相对PSA水平之间存在正相关（rho = 0.446，P < 0.0001;拟合斜率0.448，P < 0.0001），组2（rho = 0.616，P = 0.0050;拟合斜率0.438，P =0.0011）和组3（rho = 0.484，P = 0.0360;拟合斜率0.470，P = 0.0187）。数据显示前列腺癌患者中相对Gal-3和相对PSA水平的正相关性，特别是在早期临床时程。考虑到自身抗体的影响，Gal-3水平可能被认为是潜在的生物标志物，因为它与PSA水平正相关。
Galectin-3 (Gal-3), an oncogenic pro-inflammatory protein, has been suggested as a possible complementary diagnostic candidate to prostate specific antigen (PSA) blood test for prostate cancer patients. The presence of the proteins in the circulation (biomarkers) may elicit an intrinsic humoral immune reaction by generating autoantibodies, which consequently could alter the detection levels. Here, we report the associations of the two prostate cancer biomarkers, Gal-3 and PSA in patients at different clinical states of prostate cancer while taking into account the autoantibody levels. A blind, prospective, single institution, pilot study was conducted. A total of 95 men were classified into 5 groups: healthy controls (Group1), newly diagnosed patients (Group2), no recurrence after local therapy (Group3), rising PSA after local therapy (Group4), and metastatic patients (Group5). Gal-3 and PSA level were divided by their respective autoantibodies, which yielded relative PSA and relative Gal-3 levels. After the adjustments, Spearman's rank correlations and linear regression modeling revealed the positive associations between relative Gal-3 and relative PSA levels among all 95 men combined (rho = 0.446, P < 0.0001; fitted slope 0.448, P < 0.0001), in Group2 (rho = 0.616, P = 0.0050; fitted slope 0.438, P =0.0011), and Group3 (rho = 0.484, P = 0.0360; fitted slope 0.470, P = 0.0187). The data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course. Allowing for the influence of autoantibodies, Gal-3 level might be considered as a potential biomarker since it is positively associated with PSA level.